Shares of Humacyte, Inc. (NASDAQ: HUMA) plummeted around 5.9% in pre-market trading on Thursday, November 8, 2024, following the company's disappointing third-quarter earnings report. The biotechnology firm missed analyst expectations on both revenue and earnings for the quarter ended September 30, 2024.
Humacyte reported a Q3 GAAP net loss of $39.2 million, or $0.33 per share, significantly wider than the consensus estimate of $30 million loss. The company's revenue for the quarter also fell short, with operating expenses totaling $30.233 million compared to the expected $29.7 million.
The lackluster financial performance has raised concerns among investors about the company's ability to achieve profitability in the near future. Humacyte's management will likely provide further insights and guidance during the upcoming earnings call.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。